Sybrand Pretorius - PAREXEL International Senior Vice President Chief Scientific Officer

  President
Dr. Sybrand Pretorius, M.D. is Senior Vice President, Chief Scientific Officer of the Company. He is responsible for the overall leadership of a number of the Companys business units, including Global Early Phase, Global Medical Services, Quantitative Clinical Development, and Genomic Medicine. From July 2014 to August 2016, he served as Chief Scientific Officer of the Company. From July 2010 to July 2014, he served as Corporationrationrate Vice President and Worldwide Head of Early Phase with the Company. Prior to this, he served in a number of roles with the Company, including Corporationrationrate Vice President, Worldwide Head of Clinical Operations, and Vice President, Clinical Pharmacology
Age: 45  President Since 2016      
781 487-9900  http://www.parexel.com
Pretorius is a medical doctor, and holds an M.B./Ch.B degree and a master?s degree in Pharmacology from the University of the Free State, South Africa, a master?s degrees in Business Administration from Potchefstroom University, South Africa, and in Management of Drug Development from the University of Southern California.

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Ronald JanishPerrigo Company Plc
2015
Douglas BoothePerrigo Company Plc
2013
Alok SonigDr Reddys Laboratories Ltd
2015
Daniel PlewRegeneron Pharmaceuticals
2016
Heidi ChenZoetis
2012
Alejandro BernalZoetis
2015
Sandra BeatyZoetis
2012
Paul SilvaVertex Pharmaceuticals Incorpor
2019
Jatin ShahPerrigo Company Plc
2005
Louis YuPerrigo Company Plc
2013
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Stefan WeiskopfZoetis
2013
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018
Joseph LaRosaRegeneron Pharmaceuticals
2019
Amit BiswasDr Reddys Laboratories Ltd
2016
Thomas FarringtonPerrigo Company Plc
2015
Samiran DasDr Reddys Laboratories Ltd
2016
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Roxanne LaganoZoetis
2015
Kristin PeckZoetis
2018

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Currently Active Assets on Macroaxis

V   
Purchased few shares of
few hours ago
Traded for 182.01
GOOG   
Purchased few shares of
few hours ago
Traded for 1345.02
DD   
Purchased over 40 shares of
few hours ago
Traded for 64.33
V   
Purchased few shares of
few hours ago
Traded for 182.01
C   
Purchased over 40 shares of
few hours ago
Traded for 75.55
See also Your Equity Center. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Search macroaxis.com